Phase 2 trials about to start with a therapeutic vaccine, Nexvax2, that has the potential to protect coeliac patients from the adverse events caused by gluten exposure. Multicentre trials, including centres in Australia, are planned to start in mid 2018 to investigate whether regular use of the vaccine can desentisise patients with coeliac disease to ...
Coeliac “vaccine” to enter Phase 2 trials
By Tessa Hoffman
19 Apr 2018